A young person with Duchenne muscular dystrophy died following treatment with the recently approved gene therapy ...
The Company is currently analyzing the case and will update the prescribing information for Elevidys to note this development.
The patient, whom Sarepta described as a young man and later told news outlets was 16 years old, suffered acute liver failure ...
Why didn’t analysts share the same fear that gripped investors about Sarepta stock? One reason is the known risk of acute liver injury associated with adeno-associated virus vector (AAV)-based gene ...
Sarepta Therapeutics Inc.’s stock tumbled 23% on Tuesday after the biotech said a patient who used its gene therapy Elevidys for the rare disease ... has died of acute liver failure.
A young man treated with Elevidys died of acute liver failure. The case may give doctors pause before prescribing the ...
Cirrhosis typically develops over decades and is common in individuals over 50 or 60. Acute liver diseases, also known as hepatic stigmata, are typically infectious or sudden-onset conditions.
Shares of Sarepta Therapeutics have struggled for the past year due to concerns about the commercial potential of its gene ...
Dr. Arvinder Singh Soin faced an ethical challenge when a 17-year-old girl arrived in a coma with acute liver failure.
Cambridge, Mass.-based Sarepta Therapeutics reported the first known death from its Duchenne muscular dystrophy gene therapy ...
The patient underwent treatment in December with Sarepta's therapy, called Elevidys, the company told Reuters in an emailed statement. Elevidys is the only FDA-approved gene therapy for Duchenne ...
Clinical trials to continue the development of a liver dialysis device to treat those with life-threatening liver disease have been funded by a grant awarded to UCL, the Royal Free Hospital and Yaqrit ...